PMID-38330987 – Survodutide Phase 2 Obesity Dose-Finding Trial
le Roux CW, Steen O, Lucas KJ,"; Pharmacology Clinical Trials" et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162-173.
Quick Reference
| Property | Value |
|---|---|
| PMID | 38330987 |
| DOI | 10.1016/S2213-8587(23)00356-X |
| Year | 2024 |
| Journal | Lancet Diabetes & Endocrinology |
| Study Type | RCT (Phase 2, dose-finding) |
| Evidence Level | II |
| Sample | n=387 adults with obesity (BMI >=30 or >=27 with comorbidity) |
| Peptide(s) Studied | Survodutide |
Key Findings
- Mean bodyweight change from baseline to week 46: -6.2% (0.6 mg), -12.5% (2.4 mg), -13.2% (3.6 mg), -14.9% (4.8 mg), vs. -2.8% (placebo)
- At 4.8 mg, approximately 15% body weight loss — competitive with semaglutide 2.4 mg
- All survodutide doses >=2.4 mg were significantly superior to placebo
- 233 of 386 (60.4%) participants completed the 46-week treatment period
- GI adverse events occurred in 75% of survodutide recipients vs. 42% of placebo
- Nausea (44-66%) and diarrhea (19-30%) were the most common side effects
- Dose-dependent increases in heart rate were observed (a class effect of GLP-1 RAs)
- Dose-dependent reductions in waist circumference and improvements in cardiometabolic markers
Study Design
Phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Adults with obesity were randomized 1:1:1:1:1 to survodutide 0.6 mg, 2.4 mg, 3.6 mg, 4.8 mg, or placebo administered subcutaneously once weekly for 46 weeks. Dose escalation occurred over 16-20 weeks depending on the group. Primary endpoint was percentage change in body weight at week 46.
Limitations
- Phase 2 dose-finding design (not powered for hard clinical endpoints)
- High discontinuation rate (~40%) across groups
- Relatively short duration (46 weeks) for an obesity treatment
- No active comparator arm (e.g., semaglutide)
- GI tolerability was a concern, especially at higher doses
Clinical Relevance
This trial established survodutide as a promising dual GLP-1/glucagon receptor agonist for obesity, with weight loss approaching 15% at the highest dose. The glucagon receptor agonism component differentiates survodutide from pure GLP-1 RAs (semaglutide) and GIP/GLP-1 dual agonists (tirzepatide). Glucagon receptor engagement promotes hepatic lipid oxidation, increased energy expenditure, and thermogenesis — potentially addressing metabolic aspects that GLP-1-only agents do not. The Phase 3 SYNCHRONIZE program will determine whether this dual mechanism translates into superior clinical outcomes.
Related
#research #RCT #evidence-level-II #metabolic #survodutide #investigational